| Literature DB >> 33994025 |
Rahul Gupta1, Ryan Alcantara2, Tarun Popli2, Umair Tariq3, Aayaan Sood4, Sugandhi Mahajan5, Hiwot Ayele3, Yasotha Rajeswaran3, Apurva V Vyas3.
Abstract
Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling. Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension. In this review article, we will discuss the biochemical pathway of firibastat and various trials assessing drug efficacy in animals and humans. This drug has the potential to curb the risk of uncontrolled hypertension and help improve long term cardiovascular morbidity and mortality.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33994025 DOI: 10.1016/j.cpcardiol.2021.100859
Source DB: PubMed Journal: Curr Probl Cardiol ISSN: 0146-2806 Impact factor: 16.464